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ABSTRACT 
The aim of this study was to prepare and evaluate nanoparticles containing insulin in different polymer ratio by ionotropic gelation 
method. The average particle size was found to be 33.3±0.7-69.9±0.7nm. SEM indicates that nanoparticles have shown smooth and 
spherical shape. The zeta potential of optimized formulation was 35.5 mv which indicates moderate stability with no agglomeration. 
The in vitro drug release data was analyzed using zero order, first order, Higuchi, and Korsmeyer-Peppas models. It was observed 
the best fit model for nanoparticles was higuchi model. The developed formulation in situ polymeric gel is designed in such a way 
that the gel will load insulin in higher concentration and it will also contain penetration enhancer which will enhance the absorption 
of release drug from gel to systemic circulation. 
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Controlled drug delivery system (CDDS) represents the 
developed technique of pharmaceutical sciences, it’s 
includes various scientific approaches, managing for 
individual care. The drug development technology 
having abundant advantages than existing conventional 
type of dosage, it involves enhanced effectiveness, 
minimized poisoning, enhanced conformity of the 
consumer is ease 
1
. As a kind of protein and peptide 
drug, insulin is widely accepted as an effective drug for 
eliminating the clinical symptoms of diabetes mellitus 
2,3
. However, oral insulin has a very low bioavailability 
due to the destruction of gastric pH and gastrointestinal 
enzymes, as well as its low permeability across the 
intestinal epithelium 
4,5
. Currently new and potent 
Protein/Peptide drugs are generally administered 
parenterally by IV, IM and SC routes, but needle phobia 
and stress of multiple daily injections and other 
associated disadvantages lead to development of new 
and significant approaches for their delivery. Insulin is 
given subcutaneously before meal to the patients 
suffering with insulin dependent diabetes mellitus 
because insulin is inactivated in gut lumen by its 
enzymes and acidic environment and of is having very 
limited GIT permeability as well as injection phobia, 
discomfortness and cause chances of infection, make 
necessitate to discover an alternate route which can 
safely deliver insulin systematically.  
Hence, it is envisaged to design such delivery system 
and select route of administration, which will avoid 
insulin from its inactivation, absorbed effectively and 
enhance the bioavailable dose on administration. Nasal 
insulin delivery is the best way to deliver insulin safely 
without its degradation. Insulin directly enters into 
systemic circulation after absorption but low retention 
time of dosage form make nasal route is very 
challengeable. To overcome these problems, it is 
envisaged to formulate a delivery system i.e. in situ 
biodegradable polymeric gel, which can entrap insulin 
along with the penetration enhancers that will retain for 
longer period, protect and make it available to manage 
blood glucose level in the body.   
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In present study a novel drug delivery system i.e. in situ 
polymeric gel is designed in such a way that the gel will 
load insulin in higher concentration and it will also 
contain penetration enhancer which will enhance the 
absorption of release drug from gel to systemic 
circulation. Prepared formulation will remain in liquid 
form before administration but on administer nasal route 
then it will become gel due to its interaction with 
lachrymal fluid environment like pH, temperature and 
ions. Its gel form will retain for longer period of time 
and work as reservoir for insulin.  The in situ gel will 
release the drug in very sustained and controlled manner 
as well as it also increases the retention and contact time 
thus increase the bioavailability of entrapped insulin by 
making it bioavailable by increase contact time for 
longer period of time. This novel in situ gel will 
overcome the disadvantages associated with 
conventional dosage form (drop and other) like low 
retention time and immediate absorption of drug that act 
only for short time.  The in situ gel will protect insulin, 
increase its retention in ocular cavity and release it in 
very controlled manner for longer period of time which 
will reduce dose and manage blood glucose level 
effectively. 
MATERIALS AND METHODS 
Materials: 
Insulin was purchase from himedia lab, India. Chitosan 
was was obtained as a gift sample from Torrent 
Pharmaceutical Pvt. Ltd (Mumbai, India). Poloxamer 
407 was purchase from Sigma Aldrise, India. Carbopol 
934 and other chemical purchase from  himedia lab, 
India. 
Methods: 
Preparation of chitosan nanoparticles of Insulin 
Nanoparticles (NP) will be prepared according to 
Calvoet al., 1997 [6], using ionotropic gelation method 
with slight medication in which chitosan (0.4% w/v) 
will be dissolved in aqueous acetic acid solutions (1% 
v/v) (pH 6.1), while TPP (0.1% w/v) will be dissolved in 
deionized water. Insulin solution will be premixed with 
chitosan solution before the addition of the TPP solution 
drop wise into the chitosan solution under magnetic 
stirring (600 rpm) at ambient temperature for 2-4 hr. 
The obtained nanoparticles formulation will be 
lyophilized and stored in 4-8° C until it will further use. 
Optimization of process Variable 
The effect of formulation process variables such as 
stirring time, stirring speed, surfactant concentration on 
the particle size was studied. From the results obtained, 
optimum level of those variables was selected and kept 
constant in the subsequent evaluations. 
Effect of chitosan quantity  
The effect of chitosan quantity on the particle size was 
studied by varying one chitosan Chitosannanoparticles 
were prepared corresponding to varying concentrations 
of chitosan such as 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 
and 0.9% keeping the amount of Acetic acid (1% v/v), 
stirring time (3 hours) and stirring speed (600 rpm) 
constant. (Table 1) 
 
Table 1: Composition of SLN by varying amount of lipid 
Components Formulation code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Insulin 10 10 10 10 10 10 10 10 10 
Chitosan 0.1% 0.2% 0.3% 0.4% 0.5% 0.6% 0.7% 0.8% 0.9% 
Acetic acid 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 
Stirring speed (rpm) 600 600 600 600 600 600 600 600 600 
Stirring time (hrs) 3 3 3 3 3 3 3 3 3 
 
1.1.2.1 Effect of stirring time  
Different batches of chitosan nanoparticles were prepared increasing of stirring time keeping the chitosan concentration 
(0.9%)and stirring speed (600 rpm) constant. (Table 2) 
Table 2: Composition of chitosan nanoparticle by varying Stirring time 
Components Formulation code 
F10 F11 F12 F13 F14 F15 F16 F17 F18 
Insulin 10 10 10 10 10 10 10 10 10 
Chitosan 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 
Acetic acid 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 
Stirring speed (rpm) 600 600 600 600 600 600 600 600 600 
Stirring time (hrs) 1 2 3 4 5 6 7 8 9 
 
Effect of stirring speed  
Four different batches of chitosan nanoparticles were prepared corresponding to 100, 200, 300, 400, 500, 600, 700, 800 
and 900 rpm of stirring speed keeping the chitosan concentration (0.9%) and stirring time (4 Hour) constant. (Table 3) 
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Table 3: Composition of chitosan nanoparticle by varying Stirring speed 
Components Formulation code 
F10 F11 F12 F13 F14 F15 F16 F17 F18 
Insulin 10 10 10 10 10 10 10 10 10 
Chitosan 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 0.9% 
Acetic acid 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 
Stirring speed (rpm) 100 200 300 400 500 600 700 800 900 
Stirring time (hrs) 4 4 4 4 4 4 4 4 4 
 
Evaluation of nanoparticles  
Particle size analysis 
6,7
 
Particle size analysis The size distributions along the 
volume mean diameter of the nanoparticles. Particle size 
of all formulated nanoparticles was in the range between 
130.4±3.4 to 155.5±6.4 and Zeta potential of all 
formulated nanoparticle was the range between were 
measured by laser scattering light using photon 
correlation spectroscopy using a Horiba Zetasizer 
Instruments. The obtained results are shown in Figure 3.  
Entrapment efficiency 
The entrapment efficiency of the drug was defined as 
the ratio of the mass of formulations associated drug to 
the total mass of drug. Entrapment efficiency was 
determined by dialysis method. chitosan nanoparticles 
entrapped insulin were separated from the free drug by 
dialysis method. The above said formulations were 
filled into dialysis bags and the free insulin dialyzed for 
24 hours into 50 ml of buffer pH 1.2. The absorbance of 
the dialysate was measured at 272.0 nm against blank 
buffer pH 1.2 and the absorbance of the corresponding 
blank was measured under the same condition. The 
concentration of free insulin could be obtained from the 
absorbance difference based on standard curve. Standard 
curve was made by measuring the absorbance at 272.0.0 
nm for known concentrations of insulin solution 
7
.  
Drug content:  
From the prepared chitosan nano formulation 1ml of 
suspension is dissolved in the 10 ml of 1.2 pH buffer. 
The amount of insulin was determined using UV 
spectrophotometer at 272nm.The placebo formulation 
prepared similarly to drug loaded nanoparticle was used 
as blank. The total drug content was calculated 
8
.  
Shape and Surface Characterization of nanoparticle 
by Scanning Electron Microscopy (SEM): 
From the formulated batches of chitosan nanoparticle 
optimized formulations which showed an appropriate 
balance between the percentage release were examined 
for surface morphology and shape using scanning 
electron microscope Jeol Japan 6000. Sample was fixed 
on carbon tape and fine gold sputtering was applied in a 
high vacuum evaporator. The acceleration voltage was 
set at 10 KV during scanning. Microphotographs were 
taken on different magnification and higher 
magnification (200X) was used for surface morphology. 
In-vitro diffusion study: An in-vitro drug release study 
was performed using modified Franz diffusion cell. 
Dialysis membrane (Hi Media, Molecular weight 5000 
Daltons) was placed between receptor and donor 
compartments. In-situ gel equivalent to 100 mg of 
Insulin was placed in the donor compartment and the 
receptor compartment was filled with phosphate buffer, 
pH 6.5. The diffusion cells were maintained at 37±0.5°C 
with stirring at 50 rpm throughout the experiment. At 
different time interval, 5 ml of aliquots were withdrawn 
from receiver compartment through side tube and 
analyzed for drug content by UV Visible 
spectrophotometer. 
Mathematical treatment of in-vitro release data: The 
quantitative analysis of the values obtained in 
dissolution/release tests is easier when mathematical 
formulas that express the dissolution results as a 
function of some of the dosage forms characteristics are 
used. 
1. Zero-order kinetics 
9
: The pharmaceutical dosage 
forms following this profile release the same amount of 
drug by unit of time and it is the ideal method of drug 
release in order to achieve a pharmacological prolonged 
action. The following relation can, in a simple way, 
express this model: 
Qt = Qo+ Kot 
where Qtis the amount of drug dissolved in time t, Qois 
the initialamount of drug in the solution (most times, 
Qo=0) and Kois the zero order release constant (Bourne, 
2002). 
2.  First-order kinetics 
10
: The following relation 
expresses this model: 
 
where Qtis the amount of drug dissolved in time t, Qois 
the initialamount of drug in the solution and K1is the 
zero order release constant. 
In this way a graphic of the decimal logarithm of the 
released amount of drug versus time will be linear. The 
pharmaceutical dosage forms following this dissolution 
profile, such as those containing water-soluble drugs in 
porous matrices, release drug in a way that is 
proportional to the amount of drug remaining in its 
interior, in such way, that the amount of drug released 
by unit of time diminish. 
3. Higuchi model 
11
: Higuchi developed several 
theoretical models to study the release of water-soluble 
and low soluble drugs in semi-solid and/or solid 
matrixes. Mathematical expressions were obtained for 
drug particles dispersed in a uniform matrix behaving as 
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the diffusion media. The simplified Higuchi model is 
expressed as: 
 
where Q is the amount of drug released in time t and KH 
is the Higuchi dissolution constant. Higuchi model 
describes drug release as a diffusion process based in the 
Fick’s law, square root time dependent. This relation 
can be used to describe the drug dissolution from several 
types of modified release pharmaceutical dosage forms 
such as transdermal systems and matrix tablets with 
water-soluble drugs. 
4. Korsmeyer-Peppasmodel: Korsmeyeret al. used a 
simple empirical equation to describe general solute 
release behaviour from controlled release polymer 
matrices:  
 
where Mt/Mis fraction of drug released, a is kinetic 
constant, t is release time and n is the diffusional 
exponent for drug release. ’n’ is the slope value of log 
Mt/M versus log time curve 
12
. Peppas stated that the 
above equation could adequately describe the release of 
solutes from slabs, spheres, cylinders and discs, 
regardless of the release mechanism [13]. Peppas used 
this n value in order to characterize different release 
mechanisms, concluding for values for a slab, of n =0.5 
for fickian diffusion and higher values of n, between 0.5 
and 1.0, or n =1.0, for mass transfer following a non-
fickian model (Table 3). In case of a cylinder n =0.45 I 
nstead of 0.5, and 0.89 instead of 1.0. This equation can 
only be used in systems with a drug diffusion coefficient 
fairly concentration independent [13]. To the 
determination of the exponent n the portion of the 
release curve where Mt/M< 0.6should only be used. To 
use this equation it is also necessary that release occurs 
in a one-dimensional way and that the system width-
thickness or length-thickness relation be at least 10. A 
modified form of this equation was developed to 
accommodate the lag time (l) in the beginning of the 
drug release from the pharmaceutical dosage form: 
 
When there is the possibility of a burst effect, b, this 
equation becomes: 
 
In the absence of lag time or burst effect, l and bvalue 
would be zero and only at
n
is used. This mathematical 
model, also known as Power Law, has been used very 
frequently to describe release from several different 
pharmaceutical modified release dosage forms. 
 
Table 3: Interpretation of diffusional release mechanisms. 
Release exponent (n) Drug transport mechanism Rate as a function of time 
0.5 Fickian diffusion t
-0.5
 
0.5<n<1.0 Anomalous transport t
n - 1
 
1.0 Case-II transport Zero-order release 




RESULTS AND DISCUSSION 
Particle size analysis  
The size distributions along the volume mean diameter 
of the nanoparticles. Particle size of all formulated 
nanoparticles was in the range between 130.4±3.4 to 
155.5±6.4. The zeta potential of optimized formulation 
was 35.5 mv which indicates moderate stability with no 
agglomeration. The obtained results are shown in table 
4. Results showed that in formulation F-17 which 
contains higher level of chitosan and high stirring speed 
showed decrease in particle size and increase in 
entrapment efficiency, as level of chitosan decreased 
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Table 4: Evaluations of Nanoparticle formulations by OVAT 
Formulation Particle  Size (nm) Entrapment efficiency (%) Drug content (%) 
F1 55.2±0.4 71.2±0.5 69.98±0.45 
F2 45.6±0.6 62.2±0.6 73.28±0.65 
F3 60.1±0.8 65.4±0.4 70.56±0.85 
F4 48.7±0.7 63.1±0.5 65.52±0.45 
F5 55.6±1.2 61.2±0.8 66.92±0.65 
F6 69.9±0.7 60.2±0.9 68.98±0.32 
F7 65.5±0.5 59.9±0.1 71.12±0.25 
F8 55.6±0.4 60.2±0.5 69.98±0.26 
F9 65.4±0.6 58.8±0.3 73.12±0.21 
F10 52.2±0.8 63.3±0.5 70.56±0.45 
F11 41.2±0.9 60.2±0.4 69.98±0.36 
F12 52.2±0.7 65.5±0.5 73.12±0.25 
F13 45.5±0.8 68.9±0.6 75.45±0.45 
F14 55.6±0.6 73.3±0.7 73.45±0.78 
F15 60.2±0.6 75.4±0.6 78.98±0.65 
F16 45.5±0.9 79.9±0.2 85.62±0.67 
F17 33.3±0.7 82.5±0.3 89.98±0.45 
F18 65.5±0.5 78.8±0.2 75.55±0.55 
 








F17 78.8±0.2 -35.5 33.3±0.7 
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Shape and Surface morphology 
 
Figure 2: Scanning Electronic Microscopy Image of 
Optimized Formulation 
Shape and surface morphology of nanoparticles was 
studied by Scanning Electron Microscopy (SEM). SEM 
photographs of optimized formulations were shown in 
Figure 2. Insulin nanoparticles have shown smooth and 
spherical shape with different sizes depending on the 
ratios of the surfactant and polymer used. 
In Vitro drug release Study 
The in vitro release profile of optimized formulation is 
shown in fig.2. The optimized Insulin NPs showed 
initial burst release of 22.25 ± 1.3%, optimized Insulin 
NPs showed sustained drug release with maximum drug 
release of 93.32 ± 0.8% in 12 hours. Thus, it was clear 
that incorporation of Insulin nanoparticles could 
significantly sustain the release. The in vitro drug 
release data was analyzed using zero order, first order, 
Higuchi, and Korsmeyer-Peppas models. The graph for 
Higuchi model was plotted between log time and log 
percentage drug remaining and the correlation 
coefficient was found ( 2) 0.981 for in vitro drug 
release, therefore the best fit model for nanoparticles 
was higuchi model. 
 
Zero order release Kinetics of optimized 
Formulation 
 
First order release Kinetics of optimized 
Formulation 
 
Higuchi release Kinetics of optimized Formulation 
 
Graph of Peppas release Kinetics  








R² R² R² R² 
F9 0.913 0.782 0.981 0.980 
 
When the regression coefficient values of were 
compared, it was observed that ‘r’ values of Korsmeyer-
Peppas was maximum i.e. 0.980 hence indicating drug 
release from formulations was found to follow 
Korsmeyer-Peppas release kinetics. 
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CONCLUSION 
Insulin loaded polymeric nanoparticle showed slow and 
constant release of insulin from nanoparticles maintain 
constant drug plasma concentration thereby increasing 
therapeutic efficacy. In situ polymeric gel is designed in 
such a way that the gel will load insulin in higher 
concentration and it will also contain penetration 
enhancer which will enhance the absorption of release 
drug from gel to systemic circulation. Prepared 
formulation will remain in liquid form before 
administration but on administer nasal route then it will 
become gel due to its interaction with lachrymal fluid 
environment like pH, temperature and ions. Its gel form 
will retain for longer period of time and work as 
reservoir for insulin. 
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